Close Menu

NEW YORK (GenomeWeb) – Bruker said today that its board of directors has authorized a new share repurchase program under which it may purchase up to $300 million of its common stock over a two-year period beginning May 14, 2019.

The company will fund the repurchases with cash on hand and funds from its existing credit facility. The authorization does not obligate Bruker to purchase any specific number of shares and may be suspended, modified, or terminated at any time, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.